Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in December

Immunic, Inc. (NASDAQ:IMUX) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 5,640,000 shares, a growth of 14.9% from the December 15th total of 4,910,000 shares. Based on an average trading volume of 976,100 shares, the days-to-cover ratio is presently 5.8 days.

Insiders Place Their Bets

In other news, Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The shares were bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the purchase, the director now owns 87,300 shares in the company, valued at $100,395. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently bought and sold shares of the stock. HB Wealth Management LLC purchased a new position in shares of Immunic during the fourth quarter worth approximately $81,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Immunic during the third quarter worth approximately $50,000. Finally, State Street Corp raised its stake in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares in the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. D. Boral Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Immunic in a report on Tuesday, January 7th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Finally, HC Wainwright began coverage on shares of Immunic in a research report on Monday, November 25th. They set a “buy” rating and a $10.00 price target for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $12.67.

Immunic Trading Down 3.4 %

Shares of Immunic stock traded down $0.03 on Friday, reaching $0.95. The stock had a trading volume of 1,720,429 shares, compared to its average volume of 781,842. The business’s 50 day moving average is $1.11 and its two-hundred day moving average is $1.31. The company has a market cap of $85.85 million, a P/E ratio of -0.77 and a beta of 1.88. Immunic has a 1 year low of $0.95 and a 1 year high of $2.11.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.